Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
McKesson
Harvard Business School
Boehringer Ingelheim
Baxter

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MIRENA

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Mirena

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00185380 Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS) Completed Bayer Phase 2 2005-04-01 The purpose of this study is to investigate if drug doses lower than the one released from Mirena® would be as effective for contraception as Mirena®. Subjects participating in the study will be randomly assigned to be inserted with any of the three different intrauterine systems (IUSs). The IUSs are nearly alike except that the amount of hormone released from them is different.
NCT00360490 Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS) Completed Bayer Phase 3 2006-07-01 The purpose of this study is to determine whether the levonorgestrel-releasing intrauterine system is effective in decreasing menstrual blood loss.
NCT00393198 Bleeding Pattern and User Satisfaction During Second Consecutive MIRENA® in Contraception and Treatment of Menorrhagia Completed Bayer Phase 4 2006-10-01 The purpose of this study is to assess the bleeding pattern during the last 3 months of the first MIRENA® and the first year of the second MIRENA® use.
NCT00475228 IUD Insertion After D&E Procedure Completed University of Pittsburgh Phase 4 2007-03-01 This study is a randomized controlled trial of insertion of the levonorgestrel-releasing intrauterine device (LNG-IUD) immediately following dilation & evacuation (D&E) compared to delayed insertion 3-6 weeks post-abortion. Eighty-eight women undergoing D&E between 15 0/7 and 23 6/7 weeks gestation will be enrolled at Magee-Womens Hospital, Pittsburgh, PA. The primary outcome is LNG-IUD usage six months following enrollment. We hypothesize that more women receiving immediate insertion will be using the LNG-IUD 6 months after the D&E procedure than women receiving delayed insertion. Secondary outcomes include the proportion receiving an IUD, continuation rate, complication rates, subject satisfaction, and quality of life. The utility of ultrasonography in predicting expulsion will also be examined. Anticipated problems include poor subject follow-up and coordinating the intra-operative study procedures.
NCT00498784 HR-QoL and Sexuality in Mirena Inserted Contraception Users Completed Bayer Phase 4 2005-11-01 The purpose of this study is to evaluate the changes in the quality of life, as well as in the sexual activity, in women inserted with MIRENA, a hormonal contraceptive intra-uterine system, over the first 12 months of use. Patients switching from oral contraception to an intrauterine contraceptive device (here: MIRENA) will be observed in the first year post MIRENA insertion.
NCT00696202 Mirena Efficiency and Tolerability During the First Year of Use Completed Bayer Phase 4 2003-09-01 In this trial the efficacy and safety of Mirena was investigated during the first year of use
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Mirena

Condition Name

Condition Name for Mirena
Intervention Trials
Contraception 21
Menorrhagia 7
Heavy Menstrual Bleeding 3
Endometrial Hyperplasia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Mirena
Intervention Trials
Menorrhagia 13
Hyperplasia 8
Endometrial Hyperplasia 8
Hemorrhage 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Mirena

Trials by Country

Trials by Country for Mirena
Location Trials
United States 67
United Kingdom 5
Australia 5
Canada 5
Ireland 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Mirena
Location Trials
Pennsylvania 5
Texas 4
North Carolina 4
Georgia 4
Tennessee 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Mirena

Clinical Trial Phase

Clinical Trial Phase for Mirena
Clinical Trial Phase Trials
Phase 4 15
Phase 3 5
Phase 2/Phase 3 3
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Mirena
Clinical Trial Phase Trials
Completed 31
Recruiting 11
Unknown status 5
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Mirena

Sponsor Name

Sponsor Name for Mirena
Sponsor Trials
Bayer 22
Society of Family Planning 4
Emory University 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Mirena
Sponsor Trials
Other 54
Industry 25
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Colorcon
Medtronic
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.